Hirohisa Nakamae

Hirohisa Nakamae

Auto-generated profile, based on publicly available information

Hirohisa Nakamae

Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
HNHirohisa Nakamae
Hirohisa Nakamae
KTKei Tsumura
Kei Tsumura
YTYoshiki Terada
Yoshiki Terada
TNTakahiko Nakane
Takahiko Nakane
MNMika Nakamae
Mika Nakamae
MHMasayuki Hino
Masayuki Hino

5 June 2006 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
HNHirohisa Nakamae
Hirohisa Nakamae
TYTakahisa Yamane
Takahisa Yamane
THTaro Hasegawa
Taro Hasegawa
MNMika Nakamae
Mika Nakamae
YTYoshiki Terada
Yoshiki Terada
MHMasayuki Hino
Masayuki Hino
Thrombotic microangiopathy (TMA) impairs long-term survival after allogeneic hematopoietic stem cell transplantation (HSCT). As the allogeneic HSCT procedure has developed, addressing risk factors for TMA has become more complicated. The aim of this study was to investigate the impact of transplant-associated factors on TMA incidence in patients who have undergone HSCT in various settings. One hundred twenty-three consecutive allogeneic HSCT patients with hematologic diseases receiving myeloablative and reduced-intensity conditioning were evaluated retrospectively. Of 123 patients, 22 (17.9%) developed TMA after HSCT. Multivariate analysis showed the significance of GVHD grade II–IV, and the use of FK506 and the use of high-dose busulfan (Bu) (16 mg/kg) persisted. The hazard ratios of the use of FK506, the use of high-dose Bu (16 mg/kg), and GVHD grade II–IV for TMA were 8.7 (95% CI 2.0–37), 5.7 (95% CI 1.5–21), and 3.4 (95% CI 1.3–9.1), respectively. In the present study, reduced-intensity conditioning did not have an advantage over myeloablative conditioning in decreasing the incidence of TMA after HSCT. Our results also showed that high-dose Bu (16 mg/kg) for the conditioning and FK506 for the prophylaxis of GVHD might contribute more significantly to TMA onset after HSCT than other agents. Am. J. Hematol. 81:525–531, 2006.

20 January 2012 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YHYoshiki Hayashi
Yoshiki Hayashi
HNHirohisa Nakamae
Hirohisa Nakamae
TKTakako Katayama
Takako Katayama
TNTakahiko Nakane
Takahiko Nakane
HKHideo Koh
Hideo Koh
MHMasayuki Hino
Masayuki Hino
Immunomodulation induced by dasatinib is reportedly related to better prognosis in chronic myeloid leukemia (CML). However, the underlying mechanism has not yet been fully elucidated. The immunoprofiles of 63 patients in the chronic phase of CML were evaluated during treatment with a tyrosine kinase inhibitor (imatinib, n = 36; nilotinib, n = 9; dasatinib, n = 18). The numbers of CD56 + CD57 + and CD3 + CD57 + cells increased significantly in the dasatinib group. The numbers of regulatory T-cells were comparable among the three groups. Dasatinib markedly enhanced natural killer (NK)-cell reactivity. Only one patient treated with dasatinib showed a slight cytomegalovirus (CMV) reactivation. In contrast, nilotinib suppressed NK-cell reactivity. Plasma levels of interleukin-8 (IL-8), interferon-γ inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1) were significantly elevated in all three groups, and plasma levels of granulocyte macrophage-colony stimulating factor (GM-CSF) were significantly elevated in the imatinib and dasatinib groups. Our results suggest the presence of a mechanism for dasatinib-associated immunomodulatory effects that is distinct from CMV reactivation and a decreased number of regulatory T-cells.

10 July 2024 in Nature
Verified
Journal Article
Open access
PDF file
KFKosuke Fujimoto
Kosuke Fujimoto
THTetsuya Hayashi
Tetsuya Hayashi
MYMako Yamamoto
Mako Yamamoto
NSNoriaki Sato
Noriaki Sato
MSMasaki Shimohigoshi
Masaki Shimohigoshi
SUSatoshi Uematsu
Satoshi Uematsu
Changes in the gut microbiome have pivotal roles in the pathogenesis of acute graft-versus-host disease (aGVHD) after allogenic haematopoietic cell transplantation (allo-HCT)1–6. However, effective methods for safely resolving gut dysbiosis have not yet been established. An expansion of the pathogen Enterococcus faecalis in the intestine, associated with dysbiosis, has been shown to be a risk factor for aGVHD7–10. Here we analyse the intestinal microbiome of patients with allo-HCT, and find that E. faecalis escapes elimination and proliferates in the intestine by forming biofilms, rather than by acquiring drug-resistance genes. We isolated cytolysin-positive highly pathogenic E. faecalis from faecal samples and identified an anti-E. faecalis enzyme derived from E. faecalis-specific bacteriophages by analysing bacterial whole-genome sequencing data. The antibacterial enzyme had lytic activity against the biofilm of E. faecalis in vitro and in vivo. Furthermore, in aGVHD-induced gnotobiotic mice that were colonized with E. faecalis or with patient faecal samples characterized by the domination of Enterococcus, levels of intestinal cytolysin-positive E.faecalis were decreased and survival was significantly increased in the group that was treated with the E. faecalis-specific enzyme, compared with controls. Thus, administration of a phage-derived antibacterial enzyme that is specific to biofilm-forming pathogenic E. faecalis—which is difficult to eliminate with existing antibiotics—might provide an approach to protect against aGVHD.

19 August 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YTYoshiki Terada
Yoshiki Terada
HNHirohisa Nakamae
Hirohisa Nakamae
RARan Aimoto
Ran Aimoto
HKHiroshi Kanashima
Hiroshi Kanashima
ESErina Sakamoto
Erina Sakamoto
MHMasayuki Hino
Masayuki Hino
Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly improved outcome in diffuse large B-cell lymphoma (DLBL). However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma. We retrospectively evaluated the impact of the RDI of initial chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) on outcome in 100 newly diagnosed DLBL patients. A multivariate Cox regression model showed that RDI trended towards a significant association with mortality [hazard ratio per 0.1 of RDI = 0.8; 95% confidence interval 0.6-1.0; P = 0.08]. Additionally, on multivariate logistic analysis, advanced age was a significant factor for reduced RDI. Our data suggest that in DLBL patients, mortality was affected by RDI of R-CHOP as the initial treatment, and the retention of a high RDI could therefore be crucial.

30 March 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MYMasahide Yamamoto
Masahide Yamamoto
MSMaho Sato
Maho Sato
YOYasushi Onishi
Yasushi Onishi
YSYoji Sasahara
Yoji Sasahara
HSHideki Sano
Hideki Sano
Ayako AraiAyako Arai
Ayako Arai